Design and Synthesis of Pyrazole Carboxamide Derivatives as Selective Cholinesterase and Carbonic Anhydrase Inhibitors: Molecular Docking and Biological Evaluation

dc.authoridDurgun, Mustafa/0000-0003-3012-7582
dc.contributor.authorDurgun, Mustafa
dc.contributor.authorAkocak, Suleyman
dc.contributor.authorLolak, Nebih
dc.contributor.authorTopal, Fevzi
dc.contributor.authorKocyigit, Umit Muhammet
dc.contributor.authorTurkes, Cueneyt
dc.contributor.authorIsik, Mesut
dc.date.accessioned2025-05-20T19:00:05Z
dc.date.issued2024
dc.departmentBilecik Şeyh Edebali Üniversitesi
dc.description.abstractThe present study focused on the synthesis and characterization of novel pyrazole carboxamide derivatives (SA1-12). The inhibitory effect of the compounds on cholinesterases (ChEs; AChE and BChE) and carbonic anhydrases (hCAs; hCA I and hCA II) isoenzymes were screened as in vitro. These series compounds have been identified as potential inhibitors with a KI values in the range of 10.69 +/- 1.27-70.87 +/- 8.11 nM for hCA I, 20.01 +/- 3.48-56.63 +/- 6.41 nM for hCA II, 6.60 +/- 0.62-14.15 +/- 1.09 nM for acetylcholinesterase (AChE) and 54.87 +/- 7.76-137.20 +/- 9.61 nM for butyrylcholinesterase (BChE). These compounds have a more effective inhibition effect when compared to the reference compounds. In addition, the potential binding positions of the compounds with high affinity for ChE and hCAs were demonstrated by in silico methods. The results of in silico and in vitro studies support each other. As a result of the present study, the compounds with high inhibitory activity for metabolic enzymes, such as ChE and hCA were designed. The compounds may be potential alternative agents used as selective ChE and hCA inhibitors in the treatment of Alzheimer ' s disease and glaucoma. image
dc.description.sponsorshipResearch Fund of Anadolu University
dc.description.sponsorshipNo Statement Available
dc.identifier.doi10.1002/cbdv.202301824
dc.identifier.issn1612-1872
dc.identifier.issn1612-1880
dc.identifier.issue2
dc.identifier.pmid38149720
dc.identifier.scopus2-s2.0-85182631862
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1002/cbdv.202301824
dc.identifier.urihttps://hdl.handle.net/11552/8790
dc.identifier.volume21
dc.identifier.wosWOS:001146498000001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWoS
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynakWoS - Science Citation Index Expanded
dc.language.isoen
dc.publisherWiley-V C H Verlag Gmbh
dc.relation.ispartofChemistry & Biodiversity
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250518
dc.subjectPyrazole carboxamide
dc.subjectcarbonic anhydrase inhibitors
dc.subjectglaucoma
dc.subjectcholinesterase inhibitors
dc.subjectmolecular docking
dc.titleDesign and Synthesis of Pyrazole Carboxamide Derivatives as Selective Cholinesterase and Carbonic Anhydrase Inhibitors: Molecular Docking and Biological Evaluation
dc.typeArticle

Dosyalar